English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, April 14, 2021
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
エーザイ、米国神経学会年次総会にて神経領域の開発品・製品に関する最新データを発表
Monday, April 12, 2021
エーザイ、リンパ系フィラリア症の制圧活動に関するアニメーション動画がInternational Society for Neglected Tropical Diseasesフェスティバルアワード2021で「アニメーション賞」を受賞
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Wednesday, March 31, 2021
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
Tuesday, March 30, 2021
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理
Friday, March 26, 2021
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
Wednesday, July 31, 2019
エーザイ、2020年3月期配当予想の修正(増配)に関するお知らせ

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575